SWX:ROPPharmaceuticals
Assessing Roche (SWX:ROP) Valuation After New High Throughput Diagnostic Assay Launches
Roche Holding (SWX:ROP) has attracted fresh attention after announcing the cobas MPX-E assay, a CE-marked in vitro test that screens for HIV and multiple hepatitis viruses in a single high-throughput run.
See our latest analysis for Roche Holding.
Roche’s recent diagnostics launches and R&D investment news arrive while the share price sits at CHF318.0, with a 30 day share price return of a 6.8% decline but a 1 year total shareholder return of 33.17% that points to stronger long term...